ArticleThe Journal of experimental medicine2017
Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation.
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 74 citations in OpenAlex.
- Identification of EGR2 and TGFB1 as Potential Immunoregulatory Biomarkers for Allergic Rhinitis: An Exploratory Bioinformatics and Pilot Validation Study.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Granzyme K CD8⁺ T cells with tissue-resident features promote intestinal inflammation in patients with Crohn's disease.Experimental & molecular medicine · 2026Article
- MicroRNA-29a enhances and preserves stem-like CD8 T cell differentiation by regulating master epigenetic circuits of exhaustion.bioRxiv : the preprint server for biology · 2026Article
- Immune response of intestinal micrornas to transport stress in hybrid yellow catfish (tachysurus fulvidraco♀ ×t. vachellii♂) : response strategy and potential biomarker.BMC genomics · 2025Article
- Multifaceted regulatory mechanisms of the EGR family in tumours and prospects for therapeutic applications (Review).International journal of molecular medicine · 2025Review
- A minority of Th1 and Tfh effector cells express survival genes shared by memory cell progeny that require IL-7 or TCR signaling to persist.Cell reports · 2025Article
- Memory Phenotype Tfh Cells Develop Without Overt Infection and Support Germinal Center Formation and B Cell Responses to Viral Infection.European journal of immunology · 2025Article
- New insights into mesenchymal stem cells in inflammatory subtypes of asthma.Frontiers in immunology · 2025Review
- Dual single-cell and bulk RNA sequencing reveal transcriptional profiles underlying heterogenous host-parasite interactions in human peripheral blood mononuclear cells.Frontiers in immunology · 2025Article
- Physiological and pathogenic T cell autoreactivity converge in type 1 diabetes.Nature communications · 2024Article
- Transcription factor EGR2 alleviates autoimmune uveitis via activation of GDF15 to modulate the retinal microglial phenotype.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling.The Journal of biological chemistry · 2024Article
- Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.Cancers · 2024Article
- C6 Ceramide Inhibits Canine Mammary Cancer Growth and Metastasis by Targeting EGR3 through JAK1/STAT3 Signaling.Animals : an open access journal from MDPI · 2024Article
- Egr2 Deletion in Autoimmune-Prone C57BL6/lpr Mice Suppresses the Expression of Methylation-Sensitive Dlk1-Dio3 Cluster MicroRNAs.ImmunoHorizons · 2023Article
- Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction.Cancer discovery · 2023Article
- Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells.Cancer immunology, immunotherapy : CII · 2023Article
- GATA3 induces the pathogenicity of Th17 cells via regulating GM-CSF expression.Frontiers in immunology · 2023Article
- Role of Axl in target organ inflammation and damage due to hypertensive aortic remodeling.American journal of physiology. Heart and circulatory physiology · 2022Article
- Identification of differentially expressed genes and signaling pathways with Candida infection by bioinformatics analysis.European journal of medical research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Egr2 and 3 are important for maintaining immune homeostasis. Here we define a fundamental function of Egr2 and 3 operating as a checkpoint that controls the transition between clonal expansion and differentiation of effector T cells. Egr2 and 3 deficiency resulted in defective clonal expansion but hyperactivation and excessive differentiation of T cells in response to viral infection. Conversely, sustained Egr2 expression enhanced expansion but severely impaired effector differentiation. Egr2 bound to and controlled the expression of genes regulating proliferation (Myc and Myb) and differentiation repressors (Bcl6, Id3), while repressing transcription factors required for effector function (Zeb2, RORa, RORc, and Bhlhe40). Egr2 and 3 expression in T cells was regulated reciprocally by antigen and IFNγ, providing a mechanism for adjusting proliferation and differentiation of individual T cells. Thus, Egr2 and 3 are upstream regulators of effector CD4 and CD8 T cells that are essential for optimal responses with limited immunopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.